Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia.

Inclusion criteria

• Aged 18-80 years (inclusive), regardless of gender;
• ICU inpatients with a serum phosphate concentration <0.80 mmol/L, and for whom the clinician determines phosphate supplementation is required;
• Ability to receive enteral nutrition, with a daily enteral caloric intake ≥10 kcal/kg/day;
• The subject or their legal guardian fully understands the purpose and significance of this trial, voluntarily agrees to participate, provides written informed consent, and is willing to strictly adhere to the clinical study protocol and complete the study.

Exclusion criteria

• Pregnant and lactating women;
• Patients with contraindications for enteral administration, such as acute upper gastrointestinal bleeding, mechanical intestinal obstruction, severe acute pancreatitis, digestive tract fistula, gastrointestinal dysfunction, intra-abdominal hypertension, enteral feeding intolerance, or continuous gastrointestinal decompression;
• Expected ICU stay ≤96 hours;
• Known allergy to any component of the investigational drug or drugs with a similar chemical structure;
• Severe renal impairment: estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m²;
• Subjects with hyperthyroidism requiring clinical intervention;
• Subjects requiring sodium restriction;
• Other conditions deemed by the investigator as unsuitable for inclusion.